Semaglutide is perfectly tolerated without any risk of hypoglycaemia in monotherapy but suffers from gastrointestinal adverse outcomes. A large populace affected with COVID-19 infection have been diabetic; consequently usage of semaglutide in diabetic issues and also CV patients might be very much supportive in preserving health care process all through https://franciszekj554ugs7.wikipresses.com/user